• Molecular NameFlunisolide
  • SynonymMycophenylate mofetil flunisolide; Flunisolide [anhydrous]
  • Weight434.504
  • Drugbank_IDDB00180
  • ACS_NO3385-03-3
  • Show 3D model
  • LogP (experiment)2.9
  • LogP (predicted, AB/LogP v2.0)2.57
  • pkaN/A
  • LogD (pH=7, predicted)2.57
  • Solubility (experiment)Insoluble
  • LogS (predicted, ACD/Labs)(ph=7)-3.83
  • LogSw (predicted, AB/LogsW2.0)0.05
  • Sw (mg/ml) (predicted, ACD/Labs)0.06
  • No.of HBond Donors2
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds2
  • TPSA93.06
  • StatusFDA approved
  • AdministrationInhaled
  • PharmacologyA corticosteroid often prescribed as treatment for allergic rhinitis.
  • Absorption_value80.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability6.7
  • Protein binding40.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmPrimarily hepatic, converted to the S beta-OH metabolite.
  • Half life1.8 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityMusculoskeletal reactions were reported in 35% of steroid-dependent patients in whom the dose of oral steroid was being tapered and/or withdrawn. Other adverse effects reported with frequency 10% and greater include: d iarrhea, nausea and/or vomiting, upset stomach,flu, sore throat, headache, cold symptoms, nasal congestion, upper respiratory infection, unpleasant taste.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A